Psychiatr. pro Praxi, 2006; 3: 122-125

Antipsychotika v léčbě farmakorezistentní deprese

MUDr. Dagmar Seifertová CSc1, MUDr. Martin Bareš Ph.D, MUDr. Milan Kopeček2
1 Psychiatrické centrum Praha, 3. LF UK, Praha
2 Centrum neurofarmakologických studií, 3. LF UK Praha

Clinical trials indicate that approximately 50 % of depressed patients have had an inadequate response to antidepressant therapy. Poor response to adequate antidepressant treatment according treatment guidelines has been termed as treatment resistant depression (TRD). Recent data indicate that atypical antipsychotics can serve as adjunctive as well as alternative agents in the treatment of drug-resistant depressive disorder.

Keywords: treatment resistant depression, atypical antipsychotics

Published: July 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Seifertová D, Bareš M, Kopeček M. Antipsychotika v léčbě farmakorezistentní deprese. Psychiatr. praxi. 2006;7(3):122-125.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Aarnell G, Borjesson A, Eder D, Olausson B, Hetta J. Treatment resistant major depression - a comparison of fluoxetine/olanzapine combination therapy with venlafaxine. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1) P3 E013.
    2. Arsin DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord. 2005;86: 99-104. Go to original source... Go to PubMed...
    3. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2004; 16: 189-94. Go to original source... Go to PubMed...
    4. Bareš M, Kopeček M. Léčba psychotické deprese - akutní a pokračovací farmakologická léčba. Psychiatrie pro praxi, 2005.
    5. Corya S, Andersen S, Dube S: Long-term olanzapine-fluoxetine use in major depressive disorder. J Eur Coll Neuropsychopharmacol 2002, 12 (Suppl. 3): S 179, Abstract. Go to original source...
    6. Dube S, Andersen S, Paul S et al. Metaanalysis of olanzapine-fluoxetine use in treatment-resistant depression. J Eur Coll Neuropsychopharmacol 2002, 12 (Suppl. 3): S179, Abstract. Go to original source...
    7. Dunner D, Amsterdam J, Shelton R, Hassman H, Rosenthal M, Romano S. Adjunctive ziprasidone in treatment-resistantn depression: A pilot study. 2003, APA Annual meeting, NR 238, Abstract.
    8. Hirose S, Ashby C. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatr 2002, 63, 733-736. Go to original source... Go to PubMed...
    9. Hrdlička M. Combination of clozapine and maprotiline in refractory psychotic depression. EurPsychiatry, 2002, 17(8), 484. Go to original source... Go to PubMed...
    10. Kennedy SH, Eisfel B, Meyer J, Bagby R. Antidepressants in clinical practice: limitations of assesment methods and drug response. Hum Psychopharmacol 2001, 16: 105-114. Go to original source... Go to PubMed...
    11. Kennedy SH, Lam RV. Enhancing outcomes in the management of treatment resistant depression: a focus on atypical antipsychotics. Bipolar Disord 2003, 5 (Suppl. 2): 36-47. Go to original source... Go to PubMed...
    12. Kopeček M, Bareš M, Švarc J, Horáček J. Hyperprolactinemia after low dose amisulpride. Neuro Endocrinol Lett. 2004b; 25: 419-22. Go to PubMed...
    13. Kopeček M. Amisulprid. Remedia 2002; 12: 164-170. Go to original source...
    14. Macaech N, Dolberg OT, Hirschmann S, Dannon P, Grunhaus LJ. Clozapine for the treatment of agitated-depressed patients with cognitive impairment: a report of three cases. Clin Neuropharmacol. 1998; 21: 132-4. Go to PubMed...
    15. Náhůnek K, Švestka J, Mišurec J, Rodová A. Klinické zkušenosti s clozapinem. Československá psychiatrie, 71,1975, č. 1, s. 11-20.
    16. Nelson JC: Managing treatment-resistant major depresion. J Clin Psychiatry 2003, 64 (Suppl. 1): 5-12.
    17. O´Conner M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol 1998, 18: 89-91. Go to original source... Go to PubMed...
    18. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psych (1999). 60, 256-259. Go to original source... Go to PubMed...
    19. Papakostas GI, Petersen TJ, Kinrys G, Burns AM, Worthington JJ, Alpert JE, Fava M, Nierenberg AA. Aripiprazole Augmentation of Selective Serotonin Reuptake Inhibitors for TreatmentResistant Major Depressive Disorder. J Clin Psychiatry. 2005; 66(10): 1326-1330. Go to original source... Go to PubMed...
    20. Papakostas, GI, Petersen, TJ, Nierenberg, AA, et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-Resistant Major Depressive Disorder. J Clin Psychiatry 2004; 65, 217-221. Go to original source... Go to PubMed...
    21. Ranjan R, Meltzer HY. Acute and long term effectivness of clozapine in treatment resistant psychotic depression. Biol. Psychiatry 1996, 40: 253-258. Go to original source... Go to PubMed...
    22. Rappaport M, Causo C, Loescher A, Laser R. Preliminary results from the risperidone augmentation in resistant depression. APA Annual Meeting, 2003, NR 179. Abstract
    23. Rothschild JA, Williamson DJ, Tohen MF, Schatzberg A, Andersen SW, van Campen LE, Sanger (tm), Tollefson GD. A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features. J Clin Psychopharmacol 2004; 24: 365-373. Go to original source... Go to PubMed...
    24. Shelton R, Tollefson G, Tohen M. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001, 158: 131-134. Go to original source... Go to PubMed...
    25. Shelton R, Williamson DJ, Corya SA, Sanger TM, Van Campen LE, Case M, Briggs S, Tollefson GD. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistence. J Clin Psychiatry. 2005, 66(10) 1289-97. Go to original source... Go to PubMed...
    26. Schar V, Leonhardt M, Agelink A, Klieser E. Risperidone in the treatment of patients with delusional depression. Pharmacopsychiatry 1995, 28: 210.
    27. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry. 2005; 66(10): 1216-20. Go to original source... Go to PubMed...
    28. Švestka J, Votava M. Aripiprazol. Farmakoterapie 2005; 1: 239-248.
    29. Tohen M, Banov MD, Zarate CA et al. Clozapine therapy in refraktory affective disorders: polarity predics response in long-term follow up. J lin Psychiatry. 1994, 55: 295-300.
    30. Vavrušová L. Quetiapine in the treatment of non-psychotic depression. Int J Neuropsychopharmacol 2002, 5 (Suppl. 1) P2 E037.
    31. Wolfersdorf M, Barg T, Konig F, Leibfarth M, Grunewald I. Paroxetine as antidepressant in combined antidepressant-neuroleptic therapy in delusional depression: observation of clinical use. Pharmacopsychiatry. 1995; 28: 56-60. Go to original source... Go to PubMed...
    32. Wolfersdorf M, Konig F, Straub R. Pharmacotherapy of delusional depression: experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol. Neuropsychobiology. 1994; 29: 189-93. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.